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Abstract
Hundreds of genetically characterized cell lines are available for the discovery of genotype-
specific cancer vulnerabilities. However, screening large numbers of compounds against large 
numbers of cell lines is currently impractical, and such experiments are often difficult to 
control1-4. Here, we report a method called PRISM that allows pooled screening of mixtures of 
cancer cell lines by labeling each cell line with 24-nucleotide barcodes. PRISM displayed the 
expected patterns of cell killing seen in conventional (unpooled) assays. In a screen of 102 cell 
lines across 8,400 compounds, PRISM led to the identification of BRD-7880 as a potent and 
highly specific inhibitor of aurora kinases B and C. Cell line pools also efficiently formed tumors 
as xenografts, and PRISM recapitulated the expected pattern of erlotinib sensitivity in vivo.
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Cell lines have long served as tools for oncology drug discovery5. Their track record in 
predicting efficacy in patients, however, has been mixed. Cell line models have often been 
chosen more for their tractability than for their reflection of genetic diversity across human 
cancers. Unsurprisingly, generalizations from studies of few numbers of cell lines have met 
with limited success. With the ability to comprehensively characterize the genomes of 
tumors has come the recognition that the varied responses of patients to treatment are largely 
explained by the genetic diversity of cancer. Recent reports show that this diversity is 
reflected in established cell lines3, 4. It has also become possible to profile the activity of 
compounds across large numbers of cell lines and then correlate response to specific genetic 
features3, 4, 6, 7. Unfortunately, the profiling of drugs across large numbers of cell lines is 
often intractable because of the time and resources involved.
We hypothesized that the challenge of profiling hundreds of cell lines might be addressed by 
a pooled approach. Assaying cell lines in pools has the theoretical advantages of (a) 
increasing throughput and (b) allowing for internally controlled experiments (whereby each 
cell within a pool is exposed to identical drug concentrations and culture conditions). While 
cell-cell interactions or paracrine effects of different cell lines growing in a pool could, in 
principle, confound patterns of drug sensitivity observed in cell lines cultured alone, we 
reasoned that such concerns would be outweighed by the throughput advantage of a pooled 
approach. We also note that in vivo, tumors grow not as uniform masses of cells but rather as 
complex mixtures of genetically diverse tumor cells8 and non-malignant cells of the tumor 
microenvironment.
For deconvoluting pools of cancer cell lines, we used molecular barcoding because of the 
nearly limitless number of barcodes and the availability of a flexible, high-throughput (500-
plex) barcode detection system based on Luminex microspheres, which have been used in 
multiplexed assays of gene expression9, protein phosphorylation10, and in genetic screens of 
PI3-kinase inhibitor activity11
We designed the PRISM assay using lentiviral vectors which permitted stable integration of 
24-basepair DNA barcode sequences engineered to have limited sequence homology to the 
human genome. Common primer sites flanking the barcode sequence allowed for 
amplification of barcodes with a single set of primers (including one biotinylated primer). 
Amplicons were then hybridized to Luminex microspheres of distinct colors (each coupled 
to a different anti-barcode oligonucleotide) and stained with phycoerythrin-streptavidin. 
Hybridization events were then quantitated on a Luminex detector, wherein the bead color 
denotes the barcode identity and the phycoerythrin intensity reveals barcode abundance, a 
direct reflection of cell number (Fig. 1).
To establish feasibility and determine the sensitivity of PRISM, five barcoded 
adenocarcinoma cell lines were analyzed. One thousand cells each of four barcoded lines 
were plated in mixture, and the fifth line added in varying number. The following day, 
genomic DNA was harvested from the mixtures, and barcodes detected. As predicted, the 
four invariant lines showed similar signals in all mixtures, while the varied fifth line gave a 
signal directly proportional to cell number (Fig. 2a). The assay was highly sensitive, able to 
detect as few as 10 cells in a mixture of 4000 (i.e., < 0.5% of the total cell number).
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We next treated a pool of 25 lung adenocarcinoma cell lines with compounds known to have 
genotype-specific patterns of killing. To account for different doubling times of cell lines, 
each compound-treated cell line was compared to vehicle-treated controls to compute the 
relative growth inhibition of each line. Whereas treatment with puromycin resulted in 
uniform killing across the pool (Fig. 2b), treatment with the EGFR inhibitor erlotinib 
resulted in the dose-dependent killing of the 4 EGFR-mutant cell lines in the pool, 
concordant with previous studies2 (Fig. 2b and Supplementary Fig. 1). Similarly, another 
expected pattern of cell killing12 was observed with the ALK kinase inhibitor NVP-
TAE-684 (Fig. 2b): the NCI-H3122 cell line, harboring an EML4-ALK translocation, was 
sensitive to the drug, whereas NCI-H2228, with a different EML4-ALK translocation, 
exhibited intrinsic resistance
To further test the ability of PRISM to recapitulate results observed in traditional cell line 
experiments, we created a panel of 100 barcoded cell lines comprising 18 lineages and 
challenged these in 4 pools of 25 cell lines with each of 43 anticancer compounds (including 
both targeted and cytotoxic agents), yielding 3,200 measurements per compound 
(Supplementary Table 1). We saw no evidence of PRISM performance varying as a function 
of tumor type or cell lineage, although larger panels of cell lines would be required to 
exclude this definitively. As expected, PRISM revealed similar patterns of activity across the 
100 lines among functionally related compounds (e.g., microtubule binders, topoisomerase 
inhibitors, or MEK inhibitors; Supplementary Fig. 2a). For 23 compounds, we had access to 
sensitivity data across the same 100 cell lines measured by others in individual cell line 
assays measuring either ATP content (using CellTiter-Glo) or enumeration of cell nuclei 
(using an optical fluorescent imaging method, Opera)3, 13.
Using Area Under the Curve (AUC) as a measure, the traditional ATP and Nuclei readouts 
yielded similar global patterns of sensitivity (Pearson r = 0.80, p < 0.0001). PRISM yielded 
similar levels of global correlation (r = 0.72 compared to Nuclei, p < 0.0001; r = 0.66 
compared to ATP, p < 0.0001) (Fig. 2c and Supplementary Table 2). We note that the slightly 
stronger correlation between PRISM and Nuclei is expected because PRISM and Nuclei 
both represent direct readouts of cell number, whereas ATP measurement reflects a 
combination of cell number and metabolic activity.
For example, PRISM and Nuclei similarly identified hypersensitivity of BRAF-mutant 
melanoma cell lines to the BRAF inhibitor PLX4720 (Supplementary Fig. 2b). No 
significant differential sensitivity was seen to the RAF inhibitor sorafenib, now known to be 
only a weak inhibitor of the BRAF kinase1, 14 (Supplementary Fig. 2b). Similarly, PRISM 
detected a trend (p = 0.054) between BRAF mutation and sensitivity to the MEK inhibitor 
AZD6244 (acting immediately downstream of BRAF), findings consistent with clinical 
activity in patients with BRAF-mutant melanoma15 (Supplementary Fig. 2b). PRISM and 
traditional methods yielded concordant results for 21/23 of compounds tested (91%), but 
two drugs (topotecan and paclitaxel) showed slightly discordant results (Supplementary Fig. 
3). Whether these exceptions arise from the 3-day (Nuclei) vs. 5-day (PRISM) assay periods 
remains to be determined.
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We next asked whether the PRISM approach could be extended to the in vivo setting, where 
the ability to multiplex cell lines in a single xenotransplant might accelerate translational 
research. One theoretical concern was that a small number of cell lines within a pool might 
rapidly overtake the others in vivo. To test this, we injected a pool of 24 barcoded lung 
adenocarcinoma cell lines subcutaneously into each of 10 recipient NSG (NOD-SCID-
IL2Rgammanull) mice. Several weeks later, the mice were sacrificed and the tumors 
resected. Notably, PRISM detected 23/24 cell lines (96%) in each of 10 vehicle-treated 
mouse tumors. The 23 detectable lines grew at different rates, but their relative abundances 
within the tumors were nearly identical across the 10 vehicle-treated xenografts (Fig. 2d). 
Similarly, we sampled four different portions of each tumor, and found little variation in the 
contribution of particular cell lines in different parts of the tumor (e.g., Supplementary Fig. 
4). An aliquot of the initial mixture of cell lines used for injection was also passaged weekly 
in vitro for three months. As with the in vivo experiments, the vast majority of the initial cell 
lines were detectable after 98 days in culture, and the abundance of each line remained 
stable over time (Supplementary Fig. 5). These results suggest that despite differences in 
growth rates, cell mixtures may reach an equilibrium state.
Next, we investigated whether PRISM could detect the expected sensitivity of EGFR-mutant 
cell lines when treated with erlotinib in vivo. Cohorts of 10 mice each were treated daily for 
16 days by gavage with erlotinib vs. vehicle. Erlotinib treatment caused a marked reduction 
in relative abundance of 4/4 EGFR-mutant lines (by 22%, 88%, 75%, and 76%), while the 
15/19 detectable wild-type EGFR lines were either minimally affected or increased in 
proportional abundance (Fig. 2d). As a group, mutant EGFR lines were significantly 
different from wild-type EGFR lines (Kolmogorov-Smirnov D = 0.84, p = 0.0079; Fig. 2e). 
Notably, the EGFR-mutant line showing the smallest in vivo response to erlotinib 
(HCC2935) was also less sensitive to erlotinib in vitro (cf. Fig. 2b). These experiments 
demonstrate the feasibility of PRISM to assess drug sensitivity in vivo.
We next examined whether PRISM could be used not only to elucidate the differential 
cytotoxic activity of optimized compounds (drugs) but also to discover new anti-cancer 
agents. We tested 102 barcoded lines (90 non-small cell lung adenocarcinoma (NSCLC) 
lines plus 12 lines of other lineages; Supplementary Table 2). The 102 cell lines, assayed in 
4 pools of 25–27 cell lines, were screened against a library of 8,000 small molecules created 
using Diversity-Oriented Synthesis (DOS)16-18 and 400 tool compounds or oncology drugs 
with known mechanism of action19.
This large dataset allowed systematic evaluation of the PRISM assay performance. Nearly 
all of the 102 cell lines yielded sufficient signal for drug sensitivity analysis (Strictly 
Standardized Mean Difference20; Supplementary Figs. 6 and 7), despite a > 10-fold signal 
range across the panel at baseline (Supplementary Fig. 6c). While the determinants of cell 
line signal are likely multifactorial, we did observe a correlation with proliferation rate 
(Supplementary Fig. 6d), suggesting that future assays could benefit from pooling based on 
cell doubling times.
As expected, many of the oncology drugs and optimized tool compounds displayed activity 
against cell lines (Supplementary Table 3; Supplementary Fig. 7). Furthermore, compounds 
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with the same mechanism of action displayed markedly similar activity profiles across the 
cell line panel (Supplementary Fig. 8). Similarly, cell lines labeled with different barcodes 
and assayed in different pools showed similar patterns of compound activity, again reflecting 
PRISM robustness (Supplementary Fig. 9 and Supplementary Table 3).
This large dataset also allowed us to assess the ability of PRISM to reveal genotype-
phenotype relationships. Expected relationships between drug sensitivity and molecular 
features of the cell lines (from the Cancer Cell Line Encyclopedia13) were indeed observed 
in genome-wide analyses (Supplementary Table 5). For example, sensitivity to nutlin-3 
(designated BRD-A12230535), an inhibitor of the MDM2-TP53 interaction, was most 
strongly inversely correlated to the gene expression level of MDM2 (Spearman r = −0.66, p 
< 10−5). Erlotinib sensitivity demonstrated a strong inverse correlation with both EGFR gene 
expression (r = −0.61, p < 10−5) and EGFR gene copy number (r = −0.52, p = 2 × 10−5). 
Sensitivity to gefinitib (another EGFR inhibitor) showed similar correlations to EGFR gene 
expression and copy number (r = −0.51, p < 10−6 and r = −0.54, p < 10−6, respectively). 
These results suggest that beyond the well-recognized effect of EGFR mutation on 
conferring EGFR inhibitor sensitivity, EGFR expression and copy number may represent 
subtle determinants of sensitivity that are only revealed when large panels of cell lines are 
examined. As a community resource, gene expression and copy number correlates to 
sensitivity of the 370 reference compounds that showed PRISM activity are shown in 
Supplementary Table 5.
We next turned to the results of the 8000 DOS compounds screened against 102 cell lines. 
One hundred ninety-nine of the DOS compounds (2.5%) scored as hits in the primary screen 
(defined as at least one cell line being inhibited > 80% relative to control) and 139/199 
(69.8%) compounds validated in a 8-point PRISM dose-response assay (Supplementary 
Table 6). Of the 139 compounds, 49 (24.5%) killed >70% of the cell lines, suggesting that 
they were non-specific cytotoxic agents. One of the 90 selective compounds, BRD-7880, 
was examined in greater detail.
First, we asked whether the PRISM sensitivity profile across 102 cell lines could be used to 
gain insight into BRD-7880's mechanism of action by comparing its sensitivity profile to 
those of 400 tool compounds profiled in these same lines. BRD-7880 showed markedly 
similar activity to the aurora kinase inhibitor tozasertib (VX-680; Spearman r = 0.77, Figs. 
3a and 3b, Supplementary Table 7), suggesting that despite the lack of structural similarity 
between the two compounds (Fig. 3c), BRD-7880 might be an aurora kinase inhibitor. 
Treatment of HCT-116 cells with BRD-7880 resulted in polyploidy (Supplementary Fig. 
10a) and decreased phosphorylation of serine-10 in histone H3 (Supplementary Fig. 10b), 
supporting its functioning as an inhibitor of aurora kinase B (AURKB)21-23.
Biochemical kinase activity assays showed that BRD-7880 is indeed a potent inhibitor of 
AURKB and AURKC (IC50 of 7 nM and 12 nM, respectively) with less activity against 
AURKA (IC50 = 2153 nM) (Fig. 3d), a profile resembling that of barasertib (AZD1152-
HQPA; Supplementary Fig. 11). Kinetic measurements of in vitro AURKB activity 
suggested that BRD-7880 functions in an ATP-competitive manner (Supplementary Fig. 12). 
To assess the specificity of BRD-7880, kinase activity profiling was performed for 308 
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kinases, and this analysis showed that BRD-7880 is far more selective than tozasertib, 
substantially inhibiting (to < 25% control activity) only AURKB and AURKC 
(Supplementary Table 8). Similarly, in a screen of kinase-binding selectivity across 98 
kinases BRD-7880 shows highly specific binding to AURKB and AURKC (Fig. 3e and 
Supplementary Table 9). We are unaware of any other aurora kinase inhibitor with this 
degree of specificity. The result also demonstrates the utility of PRISM for rapidly 
identifying a molecular target: the target of BRD-7880 was revealed simply by virtue of its 
pattern of activity across a large panel of cell lines. Such activity would not have been 
obvious had the compound been tested on only a small number of cell lines.
PRISM will facilitate oncology drug discovery by making it feasible to rapidly test chemical 
analogs across an entire cell line panel, thus assuring that the expected on-target pattern of 
activity is retained. The facile expansion of a single vial of pooled, barcoded cells provides a 
practical solution for extending traditional compound screening to hundreds of individual 
cell lines. Furthermore, our demonstration of the feasibility of using PRISM in vivo suggests 
that cost-effective xenograft studies are possible. The bead-based barcode quantitation 
method used here has proven reliable and inexpensive, but further cost reductions will likely 
be achievable with massively parallel sequencing.
Most importantly, PRISM may facilitate cancer therapeutic discovery. Entire small-molecule 
libraries could be screened across large panels of cell lines, and compounds selected for their 
differential killing (e.g., selectively killing cells harboring “undruggable” targets). We 
believe that the cancer research community would benefit from the creation of thousands of 
genetically characterized, barcoded cell lines. With such a resource, large-scale testing of 
compounds across the diversity of human cancer types could become a routine activity.
Methods Summary
Lentiviral barcoding vector
A 6.4 kb MluI-ClaI fragment was isolated from pLenti6.2/V5DEST (Invitrogen) and ligated 
to a linker comprising oligonucleotides 5'-CGATAACTGCAGAACCAATGCATTGGA-3' 
and 5'-CGCGTCCAATGCATTGGTTCTGCAGTTAT-3'. A library of MluI-PstI linkers was 
constructed using 24-bp Luminex DNA barcodes9 placed within oligonucleotides 5'-
CGCGTXXXXXXXXXXXXXXXXXXXXXXXXCTGCA-3' and 5'-
GxxxxxxxxxxxxxxxxxxxxxxxxA-3', where XXX...XXX includes the sense barcode 
sequence and xxx...xxx includes the antisense barcode sequence, and each of these linkers 
was individually ligated into the MluI-PstI backbone of the above vector to generate 
lentiviral barcoding plasmids. Lentivirus was generated from lentivral barcoding plasmids as 
previously described24 using pCMV-dR8.2 dvpr and pCMV-VSVG packaging vectors in 
FuGENE6-transfected (Roche Corporation) HEK-293T cells; viral supernatant was 
collected after 72h, passed through a sterile 0.45μm syringe filter (VWR cat. 28144-007), 
and stored at −80°C.
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Cell lines
Cell lines were obtained through the American Type Culture Collection or provided by the 
Broad-Novartis Cancer Cell Line Encyclopedia3 and cultured in HEPES-buffered RPMI 
medium (ATCC cat. 30-2001) containing 10% heat-inactivated fetal bovine serum (Sigma 
cat. F5410) and penicillin/streptomycin G (Invitrogen cat. 10378-016). Drug sensitivity data 
of CCLE cell lines was obtained from http://www.broadinstitute.org/ccle.
Barcoding of tumor cell lines
Barcode-containing lentivirus was used to infect human tumor cell lines at 1:20 dilution with 
sham-infection controls. The following day, virus was removed and media was replaced by 
fresh media containing blasticidin (Invitrogen) at a final concentration of 3–10 μg ml−1 
media in both virally infected and sham-infected cells. Culture in blasticidin-containing 
media was continued in infected and sham-infected cells for 2–4 weeks until no sham-
infected cells survived. Barcoded lines were frozen individually and later frozen as defined 
pools.
SNP fingerprinting of cell lines
For cell line identity confirmation, we utilized 4 HX Fluidigm IFC chip loaders and 4 FC1 
cyclers for the 96.96 dynamic array. The reference set of SNP genotypes was derived from 
the Affymetrix SNP6.0 array Birdseed genotypes from the Cancer Cell Line Encyclopedia 
(CCLE)3,25. Birdseed genotypes for 42 SNPs were used as references for cell line identity. 
Fingerprints (genotypes for those same SNPs) assayed by Fluidigm after screening were 
extracted and compared to the reference set of SNPs across all CCLE lines, using the 
GenePattern FPmatching module at http://genepattern.broadinstitute.org/gp/.
PRISM compound assays
Frozen mixtures containing randomly chosen assortments of 25 to 27 barcoded cell lines 
were thawed (day −2) and replated (day −1) into 384-well microtiter plates at 50 cells per 
cell line per well. On day 0, compounds suspended in DMSO were pinned into cultures to 
achieve 8 to 16 concentrations. On day 5, cells were washed with phosphate-buffered saline 
and lysed for 60 minutes at 60°C in 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 0.45% IGEPAL 
CA-630 (Sigma cat. I8896), 0.45% Tween-20 (Sigma cat. P9416), and 10% proteinase K 
(Qiagen cat. 19133). Proteinase K was inactivated by a 15-minute incubation at 95°C.
PRISM detection
Detailed protocols of the PRISM method are available in Supplementary Methods. Genomic 
DNA from cell lysates was amplified by PCR using primers Biotin pLENTR4 (5’-Biotin-
CGTCATTACTAACCGGTACGC-3’) and pLENTF1 5’-
GGAATAGAAGAAGAAGGTGG-3’. PCR product was hybridized to Luminex beads with 
covalently attached antisense barcodes, and streptavidin-phycoerythrin addition, washing, 
and detection on Luminex FlexMap machines was performed as previously described9. PCR 
without genomic DNA was hybridized with beads to serve as background control; signal for 
each bead was subtracted from each sample measurement. DMSO-treated cell mixtures were 
used as reference control for scaling of each cell line signal at the conclusion of each 
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experiment (viability = 100 for each cell line). Thus the signal from each treated cell line 
was calculated as 100 × [(median Luminex measurement across replicates) – (median 
Luminex measurement of no DNA control)] / (median Luminex measurement of DMSO 
control).
In vivo PRISM
Barcoded cell lines grown in tissue culture were mixed in equal numbers. 2.4 × 107 cells of 
this mixture (i.e., 1 × 106 cells from each of 24 cell lines) were injected subcutaneously into 
each of 20 six-week-old male and female immunodeficient NOD SCID gamma (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) Mus musculus (Jackson Laboratories #005557) under animal 
use protocol #04-111, which was reviewed and approved by the Dana-Farber Cancer 
Institute Animal Care and Use Committee. Two unrandomized but identical groups of 
animals with ten animals per group were chosen to detect a 50% reduction in the proportion 
of a given cell line within a tumor, based on a mean proportion of 4.17% (100% ÷ 24 cell 
lines) and standard deviation of 1.5%, alpha = 0.05. Mice were treated once daily for 16 
days by gavage with either the EGFR inhibitor erlotinib (50 mg kg−1 body weight) or 
vehicle control (1% sodium carboxymethyl cellulose), beginning 12 days following injection 
of the cell lines. The tumors were resected, each tumor was cut into four portions, and the 
relative abundance of each cell line in each portion was unblindedly determined by PRISM: 
for each sample, the fluorescent signal for each cell line was converted to cell number using 
the signal from the cell mixture used for injection, and these cell numbers were used to 
calculate the relative contribution of each cell line to the tumor.
Correlation of PRISM profiles with genomic features
PRISM viability measurements in cell lines verified to be identical to Cancer Cell Line 
Encyclopedia lines using SNP fingerprint analysis were used as profiles to query previously 
reported genome-wide features (gene expression and copy number) of cell lines in the 
Cancer Cell Line Encyclopedia13. Among the pairs of duplicate cell lines, the cell line with 
the higher baseline PRISM signal was selected for genomic correlation analysis. Three cell 
lines which showed markedly decreased baseline signals in control wells (COR-L23 [094], 
NCI-H2228 [029], and NCI-H661 [051]) were excluded from correlation analyses. 
Spearman's rank correlation was computed using the PRISM AUC measurement from each 
compound versus either gene expression or copy number, and the significance of correlation 
was calculated using permutation testing with 106 iterations. All genomic data for these cell 
lines are available at http://www.broadinstitute.org/ccle.
In vitro kinase inhibition assays
Incorporation of radioactivity from 10 μM γ-33P-ATP was measured in in vitro kinase 
assays across 8 doses in duplicate by the EMD Millipore KinaseProfiler service (Billerica, 
MA) under published standard conditions with 10 mM ATP. Full-length human AURKA 
was assayed with 200 μM LRRASLG (Kemptide); full-length human AURKB with 30 μM 
AKRRRLSSLRA; and full-length human AURKC with 30 μM AKRRRLSSLRA. IC50 
values were modeled using least-squares and variable slope with Prism 6.0 software 
(GraphPad, San Diego, CA).
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KinaseProfiler profiling
Specificity of in vitro kinase inhibition by BRD-7880 (30 nM) or tozasertib (30 nM) was 
performed by EMD Millipore (Dundee, United Kingdom) using standardized protocols.
KinomeScan profiling
Kinase binding was performed by DiscoveRx (Fremont, CA) using their KinomeScan 
method, using the scanEDGE profile (97 kinases) plus the inclusion of AURKC (total 98 
kinases). Images were generated using TREEspot™ Software Tool and reprinted with 
permission from KINOMEscan, a division of DiscoveRx Corporation.
AURKB in vitro kinase assays
Enzyme kinetic experiments were performed at pH 7.0 in 8 mM MOPS buffer with 0.2 mM 
EDTA and 10 mM magnesium acetate. Reactions were assembled in 384-well plate wells by 
adding 400 ng/ml of AURKB (EMD Millipore cat. no. 14-835) into separate reaction 
mixtures containing 1.5μM fluorescently labeled Caliper peptide substrate (FL-peptide 1, 5-
FAM-AKRRRLSSLRA-COOH, Perkin-Elmer cat. no. 760345) with various concentrations 
of ATP and compound (BRD-7880, tozasertib, barasertib). The final ATP concentrations 
varied from 6.25 to 200 μM and compound varied from 0 to 200 nM. Plates were 
immediately placed into a Perkin-Elmer Caliper LabChip EZ Reader and wells were 
sampled periodically throughout a 1-hour reaction period for initial reaction rate. The 
fluorescent product and substrate were separated and monitored on the Caliper microfluidic 
instrument. The conversion of substrate was calculated with Caliper software. Km and ki 
values were determined from the double reciprocal Lineweaver-Burk plot by linear 
regression with GraFit 6 software (Erithacus Software Ltd., Horley, U.K.) using competitive 
inhibition equation modeling.
DNA content analysis
HCT-116 cells were treated with 10 μM of DMSO, barasertib, GSK1070916, MLN8054, 
BRD-7880, or tozasertib. 24 hours or 48 hours following treatment, cells were stained with 
propidium iodide and DNA content per cell was assessed using a BD LSR II flow cytometer 
(BD Biosciences, Franklin Lakes, NJ).
Western blotting
HCT-116 cells were treated with 10 μM of DMSO, barasertib, GSK1070916, MLN8054, 
BRD-7880, or tozasertib. Cells lysates were probed on Western blot using antibodies 
(diluted 1:1000) to histone H3 (Abcam cat. 24834), phosphoserine10-histone H3 (Cell 
Signaling Technology cat no. 3377SS), aurora kinase B (Millipore cat. no. 04-1036), or 
beta-actin (Santa Cruz Biotechnology cat. no. sc-47778) and detected using a LI-COR 
Odyssey analyzer (LI-COR Biosciences, Lincoln, NE).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. PRISM method
24-basepair DNA barcodes encoded within lentiviruses are stably integrated into individual 
tumor cell lines after blasticidin selection, and barcoded cell lines are individually frozen 
and later thawed to generate mixtures of equal numbers of barcoded cell lines, which are 
frozen again. Thawed mixtures are plated and then rearrayed into tissue culture assay plates. 
Mixtures are treated with test compounds or vehicle (DMSO) controls. At assay conclusion, 
genomic DNA is harvested from the mixture of remaining viable cells. Barcode sequences 
are amplified using polymerase chain reaction and universal primers (one of which is 
biotinylated), and amplified sequences are hybridized to individual microbeads harboring 
antisense barcode sequences and then to streptavidin-phycoerythrin. A Luminex FlexMap 
detector quantitates fluorescent signal for each bead. To adjust for differing barcoding 
efficiencies and differing cell doubling, the signal for each barcoded cell line is scaled to that 
of vehicle-treated control, thus demonstrating relative inhibition profiles for specific test 
compounds across multiple cell lines in mixture.
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Figure 2. PRISM in vitro and in vivo
a. Barcode signal is proportional to cell number. Five human lung adenocarcinoma cell 
lines (NCI-H1437, PC-9, NCI-H2077, Calu-6, and A549) were labeled with lentivirus 
encoding one of five specific 24-basepair DNA barcode sequences and driving expression of 
the bsd blasticidin resistance gene; each cell line was selected for blasticidin resistance. 
Designated numbers of cells were plated together in mixture in a well of a 96-well tissue 
culture plate: 1000 cells each of four cell lines (NCI-H1437, PC-9, NCI-H2077, and Calu-6) 
and 0–1000 cells of one cell line (A549). The following day, genomic DNA was prepared 
from cell mixtures, and polymerase chain reaction-amplified barcodes were hybridized to 
microbeads corresponding to each barcode; quantitative fluorescent signals were read on a 
Luminex FlexMap detector. The fluorescent Luminex signal for barcoded A549 cells (mean 
± S.E.M., n = 4) is directly proportional to the number of cells.
b. Relative inhibition profiles of erlotinib, NVP-TAE-684, and puromycin in a mixture of 25 
barcoded lung adenocarcinoma cell lines (non-small cell lung carcinoma, NSCLC) in 
mixture. Twenty-five barcoded lung adenocarcinoma cell lines were tested in mixture 
against varying concentrations of the epidermal growth factor receptor (EGFR) inhibitor 
erlotinib or the anaplastic lymphoma kinase (ALK) inhibitor NVP-TAE-684 (at 0–10 μM) or 
the ribosomal inhibitor puromycin (at 0–10 μg/ml) and viability relative to DMSO-treated 
control is plotted as a color gradient. Cell lines are listed with bracketed barcode numbers. 
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EML4-ALK, cell lines containing EML4-ALK translocations; EGFR mut, cell lines 
containing EGFR mutations. See text for details.
c. Area under the curve comparisons of cell viability measures with PRISM. Three methods 
were used to determine cell viability after subjecting 100 human cancer cell lines 
(representing 18 tissues of origin)—either individually (ATP using CellTiter-Glo, or Nuclei 
using Opera) or in 4 mixtures of 25 cell lines (PRISM)—to 23 antitumor compounds at 8 
concentrations. The AUC (Area Under the Curve) for the viability vs. log(concentration), 
scaled to 1 (=100% viability over all concentrations), was determined for each cell line–
compound combination for each method by taking the mean viability across all tested 
concentrations, and pairwise correlations between the methods are shown. Pearson 
correlation of ATP vs. Nuclei (left panel) r = 0.80, p < 0.0001; ATP vs. PRISM (center) r = 
0.66, p < 0.0001; Nuclei vs. PRISM (right) r = 0.72, p < 0.0001.
d. Relative tumor cell line growth in mixture in animals. PRISM was used to quantitate 
barcode signals from tumors in 10 erlotinib- and 10 vehicle-treated animals. Tumor barcode 
signals were scaled first to corresponding barcode signals of the injected cell mixture to 
determine the number of cell equivalents; the scaled signal for each barcode line was then 
used to determine the percentage contribution of each tumor cell line to the mixture. The 
same 23 of 24 lines were detected in all 10 vehicle-treated animals. Circles denote mean 
percentage tumor volume; error bars denote standard error of the mean across 10 animals in 
each group.
e. EGFR mutation status and response to erlotinib in animals. Within tumors, EGFR 
mutation in cell lines was associated with a significant decrease in relative cell number (log 
ratio of percentage of tumor of each cell line in erlotinib-treated over vehicle-treated) 
compared to wt EGFR in cell lines (two-sided two-sample Kolmogorov-Smirnov test, D = 
0.84, p = 0.0079). Median ± interquartile ranges are shown for each group.
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Figure 3. BRD-7880 inhibits aurora kinase B
a. Comparison of PRISM profiles across 102 cell lines for BRD-7880 (0.25, 0.5, 1, 2, 4, 8, 
16, 32 μM) or tozasertib (0.07, 0.13, 0.26, 0.52, 1, 2, 4, 8 μM).
b. Correlation of PRISM AUC between BRD-7880 (a.k.a. BRD-K01737880) and tozasertib. 
Area under the curve (AUC) of viability vs. concentration curve was calculated for each cell 
line across 8 doses of compound. Least-squares (ordinary fit) regression line is shown with 
95% confidence bands. Spearman r = 0.77.
c. Structures of BRD-7880 and tozasertib.
d. In vitro aurora kinase assays. Incorporation of radioactivity from 10 μM γ-33P-ATP was 
measured in in vitro kinase assays across 8 doses in duplicate by the EMD Millipore 
KinaseProfiler service under published standard conditions with 10 mM ATP. Full-length 
human AURKA was assayed with 200 μM LRRASLG (Kemptide); full-length human 
AURKB with 30 μM AKRRRLSSLRA (ribosomal protein S6 peptide); and full-length 
human AURKC with 30 μM AKRRRLSSLRA. IC50 values were modeled using least-
squares and variable slope with GraphPad Prism 6.0 software.
e. KinomeScan profile for BRD-7880 across 98 kinases. Left, schematic representation of 
relative affinity of BRD-7880 for specific kinases in the KinomeScan assay (data available 
in Supplementary Table 9). Green circles represent tested kinases for which BRD-7880 
decreases binding < 75% control. Right, published relative affinities of tozasertib (VX-680) 
for same 98 kinases (where available 26, 27).
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